News | April 01, 2022
Oragnon enters global licencing agreement with Dare Biosciences
An estimated 21 million American women experience BV
An estimated 21 million American women experience BV
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Air purification system achieves Intertek zero ozone certification
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
Subscribe To Our Newsletter & Stay Updated
